Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CRVO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Forecast
559%2026-Revenue
-199%2026-EPS
159%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
16.00(62.77%)
Number of analyst
1
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Buy
2024-12-17
Now: Neutral
Morgan Stanley
downgradePrevious: Overweight
2024-12-11
Now: Underweight
Chardan Capital
initialisePrevious: Not converted
2024-09-18
Now: Buy
Morgan Stanley
initialisePrevious: Not converted
2024-07-26
Now: Overweight
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.70
vs -2.06
Q4.23
N/A
-0.38
vs -3.00
Q1.24
N/A
-0.41
vs -3.01
Q2.24
N/A
-0.27
vs -1.04
Q3.24
N/A
-0.55
vs -0.70
Q4.24
N/A
-0.80
vs -0.38
Q1.25
N/A
-0.56
vs -0.41
Q2.25
N/A
-0.70
vs -0.27
Q3.25
N/A
-0.61
vs -0.55
Q4.25
N/A
-0.43
vs -0.80
Sales Growth
YoY
Current
Estimates
Q3.23
NA
1.5M vs NA
Q4.23
NA
2.5M vs NA
Q1.24
+67%
2.3M vs 1.4M
Q2.24
NA
3.3M vs NA
Q3.24
+27%
1.9M vs 1.5M
Q4.24
-13%
2.2M vs 2.5M
Q1.25
-18%
1.9M vs 2.3M
Q2.25
-47%
1.8M vs 3.3M
Q3.25
-31%
1.3M vs 1.9M
Q4.25
-41%
1.3M vs 2.2M
Return on Equity
QoQ
Q1.23
-25%
-0.25
vs -0.20
Q2.23
-15%
-0.15
vs -0.25
Q3.23
+22%
0.22
vs -0.15
Q4.23
-32%
-0.32
vs 0.22
Q1.24
-47%
-0.47
vs -0.32
Q2.24
-5%
-0.05
vs -0.47
Q3.24
-10%
-0.10
vs -0.05
Q4.24
-17%
-0.17
vs -0.10
Q1.25
-14%
-0.14
vs -0.17
Q2.25
-19%
-0.19
vs -0.14
Institutionnal Ownership
QoQ
Q4.22
NA
NA
vs NA
NA
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
12
12
vs NA
NA
Q4.23
12
12
vs 12
NA
Q1.24
20
20
vs 12
67%
Q2.24
38
38
vs 20
90%
Q3.24
48
48
vs 38
26%
Q4.24
41
41
vs 48
-15%
Q1.25
45
45
vs 41
10%
globenewswire.com
7 hours ago
globenewswire.com
8 hours ago
zacks.com
10 hours ago
zacks.com
10 hours ago
benzinga.com
11 hours ago
Quote Panel
Key Metrics
Relative Strength
CRVO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
-0.29Â ( -2.87%)
Pre-market 10.36$0.53 (5.34%)
Relative Strenght
40
Volume Buzz
-33%
Earning Acce
No
Dist 52w H.
52%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How CRVO compares to sector?
CRVO
-4x
